Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.54 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | CYCS | P99999 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17668308 | 0.98 | TERT (0.53) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL2555721 | 0.98 | TERT (0.53) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL2553050 | 0.97 | TERT (0.51) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL2555716 | 0.97 | TERT (0.52) | TERTTOP1 | |
| Hydrochloric Acid SCHEMBL2553046 | 0.97 | TERT (0.52) | TERTTOP1 | |
| SCHEMBL4552175 | 0.93 | TERT (0.58) | TERTTOP1CYCS | |
| SCHEMBL14999536 | 0.89 | TERT (0.46) | TERT | |
| SCHEMBL4271237 | 0.89 | TERT (0.46) | TERT | |
| SCHEMBL4263240 | 0.89 | TERT (0.46) | TERT | |
| SCHEMBL15003039 | 0.89 | TERT (0.46) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564697-A | Application of G four-chain ligand and entecavir combined medication in anti HBV infection | 武汉大学 | 2025-03-07 | — | — | CN | disclosed |
| US-20240390328-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT COMPOUND CONJUGATED TO G4 STRUCTURES OF CORONAVIRUSES FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES | Research & Business Foundation Sungkyunkwan University (KR) | 2024-11-28 | — | — | US | disclosed |
| WO-2022060209-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT COMPOUND CONJUGATED TO G4 STRUCTURES OF CORONAVIRUSES FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES | 성균관대학교산학협력단 | 2022-03-24 | — | — | WO | disclosed |
| EP-3431088-A1 | MNTBAP FOR USE IN INDUCING A TRANSIENT IMMUNE TOLERANCE | Paris Sciences et Lettres - Quartier Latin (FR) | 2019-01-23 | — | — | EP | disclosed |
| US-8987245-B2 | Composition and method for affecting obesity and related conditions | PARKER JONATHAN R BRESTOFF (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140357610-A1 | COMPOSITION AND METHOD FOR AFFECTING OBESITY AND RELATED CONDITIONS | PARKER JONATHAN R BRESTOFF (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140243294-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759324-B2 | Method of activation of oxazaphosphorines | DUKE UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130172296-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | UNIV DUKE (US) | 2013-07-04 | — | — | US | disclosed |
| US-8399434-B2 | Method of activation of oxazaphosphorines | DUKE UNIVERSITY (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2008073195-A2 | METHOD FOR ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080113956-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2008-05-15 | — | — | US | disclosed |
| US-20070179124-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2007-08-02 | — | — | US | disclosed |
| US-20060074062-A1 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2006-04-06 | — | — | US | disclosed |
| US-6916799-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040058902-A1 | Substituted porphyrins | DUKE UNIVERSITY | 2004-03-25 | — | — | US | disclosed |
| US-20040039211-A1 | Tetrapyrroles | DUKE UNIVERSITY AND NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-02-26 | — | — | US | disclosed |
| EP-1045851-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030069281-A1 | Tetrapyrroles | GOODNOW CAPITAL, L.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | DUKE UNIVERSITY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113956-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20070179124-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | LPO, PRDX5, MPO | TERT 3237/4885TOP1 4338/4885CYCS 265/4885 |
| US-20060074062-A1 | Substituted porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20140243294-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885TOP1 1564/4885CYCS 888/4885 |
| US-20040058902-A1 | Substituted porphyrins | SOD1, SOD3, CAT | TERT 1933/4885TOP1 2957/4885CYCS 190/4885 |
| US-20030069281-A1 | Tetrapyrroles | PPOX, TXNRD2, PRDX5 | TERT 1022/4885TOP1 4311/4885CYCS 204/4885 |
| US-20040039211-A1 | Tetrapyrroles | PPOX, TXNRD2, PRDX5 | TERT 1022/4885TOP1 4311/4885CYCS 204/4885 |
| US-20240390328-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AS ACTIVE INGREDIENT COMPOUND CONJUGATED TO G4 STRUCTURES OF CORONAVIRUSES FOR PREVENTION OR TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES | SARS1, GTF3C4, GTF3C5 | TERT 3233/4885TOP1 708/4885CYCS 3757/4885 |
| US-20130172296-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885TOP1 1564/4885CYCS 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.